Cara Therapeutics Announces Positive Top-Line Results From

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cara Therapeutics Announces Positive Top-Line Results From Phase 1a / 1b Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
  • All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration
  • Establishes dosing range and regimen for Phase 2 trial design

SHELTON, Conn., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA ), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the successful completion of a Phase 1a / 1b clinical trial of an oral tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.

The double-blind, randomized, placebo-controlled trial evaluated the pharmacokinetic and safety profile of single and multiple escalating doses of Oral CR845 in 150 healthy volunteers at a single U.S. site. The single ascending dose study, which included six tablet strengths ranging from 0.1 mg to 10 mg, demonstrated a mean oral bioavailability of 10% across all dose groups under fasting conditions, with a range of maximum plasma concentrations of CR845 bracketing the concentrations seen in previously successful Phase 2 trials with I.V. CR845. All tested dose strengths were also shown to be active at the kappa opioid receptor, as assessed by statistically significant (p<0.0001) acute changes in blood measurements of an established neuroendocrine biomarker.

The multiple ascending dose study, which used repeat dose studies of the 0.1 mg, 1 mg and 5 mg tablets, administered twice a day (b.i.d.) for one week, demonstrated that all tablet doses were well tolerated with no serious adverse events (SAEs) reported and all adverse events (AEs) were mild and generally similar to those reported with I.V. CR845. Additionally, clinical safety laboratory measurements were normal across all tablet strengths after single or repeat dosing.

"Successful completion of this Phase 1 trial of the tablet formulation of Oral CR845 represents a key milestone for Cara as we look to expand the clinical development of CR845 beyond the treatment of acute pain in a hospital setting," said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. "We are very encouraged that the plasma levels of CR845 attained within this tablet strength range equaled or exceeded those previously associated with clinical analgesic effects seen in acute post-operative pain models with I.V. CR845."

Dr. Chalmers also noted, "These findings complement our recently successful human abuse liability study of I.V. CR845, as well as our recently completed quantitative primary research study indicating that Oral CR845 has the potential to meet a significant physician demand for a safer, non-abusable alternative to narcotic opioids and NSAIDs for the treatment of moderate-to-severe acute and chronic pain."

About CR845

CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain. In multiple randomized, double blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in pain intensity and opioid-related side effects. In over 400 subjects dosed to date, I.V. CR845 was found to be safe and well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists. In a human abuse liability trial, I.V. CR845 met the primary endpoint showing highly statistically significant reductions (p < 0.0001) in scores for "drug liking," as well as "feeling high," "overall liking," and "take drug again" when compared to I.V. pentazocine, a Schedule IV opioid analgesic.

About Tablet Formulation of Oral CR845

The oral tablet formulation of CR845 was synthesized utilizing the peptide formulation technology developed by Enteris Biopharma under a Manufacturing and Clinical Supply Agreement.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company's planned Phase 2 clinical trial of the tablet formulation of oral CR845, potential ability of oral CR845 to meet significant physician demand, the likelihood of physicians prescribing oral CR845 if regulatory approval is received, and the potential future regulatory and development milestones for the Company's product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics' filings with the Securities and Exchange Commission, including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2013 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CORPORATE CONTACT: Derek Chalmers President & CEO Cara Therapeutics, Inc. 203-567-1500 MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations 212-362-1200

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 54

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 250

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 106

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 82

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 176

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 106

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 103

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 0

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 80

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Gene Therapy Brings Hope to Young Patients

Updated Category News Views 279

Transformative Journey of Gene Therapy for AADC Deficiency Laughter and joy filled the sunny lobby of a research clinic, where a spirited little boy named Sriansh Ojha played happily with his sister, marking a dramatic contrast to his early life struggles. This remarkable transformation is largely due to gene therapy, a groundbreaking treatment that has changed the...

Continue Reading
Damon Inc. Unveils $30 Million Equity Offering for Mobility Innovation

Updated Category News Views 224

Introduction to Damon's Innovative Strategy Damon Inc. has recently announced a substantial $30 million Regulation A+ equity offering, which is set to enhance its impressive lineup of personal mobility products. The company, renowned for its electric motorcycles, aims to leverage the proceeds not only to fuel innovation in its products but also to fortify its...

Continue Reading
Cindy Eckert: Shaping the Future of Women's Health Together

Updated Category News Views 375

Cindy Eckert's Impact on Women's Health Innovation Cindy Eckert, the remarkable Founder and CEO of Sprout Pharmaceuticals, has been announced as the keynote speaker for the highly anticipated Women's Health Summit at Harvard Business School. This significant event, scheduled for 2025, aims to unite leaders, investors, and innovators dedicated to transforming women's...

Continue Reading
VoiceBrain and Diga-Talk Forge Partnership to Enhance Communications

Updated Category News Views 270

VoiceBrain and Diga-Talk Solutions Collaborate for Innovation In a groundbreaking partnership, VoiceBrain, renowned for its AI voice analytics, has teamed up with Diga-Talk Solutions, specialists in Push-to-Talk (PTT) over cellular technology. This exciting collaboration was unveiled during a prominent industry event, aiming to revolutionize real-time communication across...

Continue Reading
AstaReal's Research Reveals Astaxanthin Benefits for Kids' Eyes

Updated Category News Views 234

AstaReal's Groundbreaking Research on Astaxanthin AstaReal, Inc. has made a significant advancement in understanding children's eye health with its innovative research on astaxanthin. This powerful antioxidant, derived from the microalgae Haematococcus pluvialis, has been recognized globally for its benefits in enhancing visual performance, particularly in adults....

Continue Reading